MediWound Ltd (MediWound) is developing enzymatic therapeutics that specialize in non-surgical tissue repair. The company’s leading product, NexoBrid, is a topically applied biological agent that utilizes proteolytic enzymes enriched with bromelain to selectively remove nonviable burn tissue, or eschar, in patients suffering from deep partial and full-thickness thermal burns. NexoBrid is approved in over 40 countries, including the US and European Union, and has received designation as an orphan biologic drug. Its rapid action allows for eschar removal within four hours without damaging surrounding healthy tissue. It has Patents pf Over 80 patents granted, with 37 in force and 13 pending patent applications as of December 31, 2025. It has also gained US Food and Drug Administration approval for pediatric use, allowing treatment for patients from newborns to eighteen years old. MediWound is advancing EscharEx, a bioactive, multimodal debridement therapy for chronic and hard-to-heal wounds, currently in advanced clinical development stages. EscharEx is designed for easy, daily topical application and has shown safety and efficacy in several Phase II trials. It effectively promotes granulation tissue formation and reduces bioburden and biofilm, preparing the wound bed for healing. A Phase III study for venous leg ulcers is planned, with preparations already underway for a Phase II/III study targeting diabetic foot ulcers. MediWound is also developing MW005, an innovative topical biological drug aimed at treating low-risk basal cell carcinoma (BCC). Initial Phase I/II trial results indicate that MW005 is safe, well-tolerated, and demonstrates effective clearance of target lesions, providing proof of concept for clinical efficacy.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

MediWound's research and development strategy is centered around its validated proteolytic enzyme platform technology, focusing on next-generation protein-based therapies for burn and wound care, and for tissue repair. This platform underlies NexoBrid and EscharEx, and is being developed into additional product candidates for high-value indications. The company conducts clinical and preclinical studies to support the efficacy and safety of its products and their ingredients, and to extend and validate their benefits for human health. The company’s R&D units are located at its facilities in Yavne and Gan-Rave, Israel. These units are responsible for managing the company's research and development activities, including planning, designing, executing, analyzing, and publishing clinical studies. The R&D team coordinates project planning, trial design, execution, outcome analyses, and clinical study report submission, consulting with key opinion leaders and top-tier consultants to optimize design and execution. The company’s pipeline products include NexoBrid and EscharEx. In FY2025, the company invested US$13.4 million in R&D, a 63.5% year-over-year decline, representing 79% of its revenue.